H. Pylori Eradication: The Complete Guide to Triple Therapy, Antibiotic Resistance, and Full Recovery

What Exactly Is H. Pylori — and Why Is It Everywhere?

Helicobacter pylori is a gram-negative, spiral-shaped bacterium that colonises the gastric mucosa — the inner lining of the stomach. Its discovery by Barry Marshall and Robin Warren in 1982 (Nobel Prize, 2005) overturned decades of medical dogma that held that the stomach was too acidic to harbour living organisms. Marshall famously drank a culture of H. pylori himself to prove the causal link to gastritis, developing symptoms within days.

What makes H. pylori so globally prevalent is a combination of features no other known pathogen shares: it produces the enzyme urease, which converts urea to ammonia, neutralising the acid immediately around the bacterium. It burrows beneath the stomach's mucus layer, shielded from acid, immune cells, and most antibiotics. And crucially, it has co-evolved with humans for at least 60,000 years — the dominant strain types even allow epidemiologists to trace ancient human migration routes.

How Transmission Occurs

H. pylori spreads primarily via the oral-oral and fecal-oral routes. In high-prevalence regions (much of Africa, Southeast Asia, and South America), infection rates exceed 70% and most transmission occurs in early childhood within family units — through shared utensils, food, or water contaminated with fecal material. In low-prevalence regions like Northern Europe, North America, and Australia, rates have fallen below 30–40% largely due to improved sanitation and smaller household sizes. The bacterium is rarely acquired in adulthood.

Who Is Most at Risk?

• Children in low-income households with crowded living conditions
• Individuals in regions with untreated or poorly treated municipal water
• People sharing utensils or food with an infected person
• Immigrants from high-prevalence countries
• Anyone with a first-degree relative with peptic ulcer disease or gastric cancer

Once established, H. pylori infection is essentially permanent without deliberate antibiotic eradication. The immune system mounts a chronic inflammatory response but cannot clear the organism. This persistent low-grade inflammation — chronic active gastritis — is the foundation from which peptic ulcer disease, atrophic gastritis, intestinal metaplasia, and eventually gastric cancer may develop over decades.

From Infection to Disease: Peptic Ulcers, MALT Lymphoma, and Cancer

The majority of people infected with H. pylori — roughly 80% — will never develop clinically significant disease. But the minority who do face outcomes that range from painful (peptic ulcers) to life-threatening (gastric cancer). The spectrum of disease is shaped by bacterial virulence factors, host genetics, and environmental cofactors including diet, smoking, and NSAID use.

Peptic Ulcer Disease

H. pylori is responsible for approximately 90% of duodenal ulcers and 70–80% of gastric ulcers. The mechanism involves multiple pathways: urease-generated ammonia directly damages mucosal cells; the bacterium disrupts the protective mucus layer; and the inflammatory cascade increases gastric acid secretion. The net result is that the stomach's defences are overwhelmed and the underlying mucosa erodes into an ulcer.

Symptoms include burning epigastric pain (classically relieved by eating for duodenal ulcers, worsened by eating for gastric ulcers), nausea, bloating, and early satiety. Complications — bleeding, perforation, and gastric outlet obstruction — carry significant mortality and hospitalisation burdens. Crucially, eradicating H. pylori heals ulcers definitively in a way that acid suppression therapy alone never achieves: without eradication, annual ulcer recurrence rates are 60–80%; after successful eradication, they fall below 5%.

MALT Lymphoma

Mucosa-associated lymphoid tissue (MALT) lymphoma is a rare but clinically significant consequence of chronic H. pylori infection. The stomach normally contains no lymphoid tissue; it develops in response to persistent bacterial antigen stimulation. Low-grade gastric MALT lymphoma is almost exclusively driven by H. pylori — and in a striking demonstration of disease reversibility, H. pylori eradication alone produces complete remission in approximately 75–80% of low-grade cases. This remains one of the few examples of antibiotic therapy curing cancer.

Gastric Adenocarcinoma

The WHO classifies H. pylori as a Group 1 carcinogen — a definite cause of cancer in humans. It is the primary driver of non-cardia gastric adenocarcinoma, the third leading cause of cancer death worldwide. The pathway from infection to cancer follows a defined sequence known as the Correa cascade: normal mucosa → chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma. This progression takes decades, which creates a meaningful window for intervention.

Virulence factors determine which infected individuals are at highest cancer risk. The CagA (cytotoxin-associated gene A) protein is the most studied: strains carrying the cagA gene are associated with significantly higher risks of peptic ulcer and gastric cancer compared to cagA-negative strains. The VacA (vacuolating cytotoxin A) gene also contributes, with specific allelic combinations (s1/m1) conferring the highest pathogenicity.

Diagnosing H. Pylori: Which Test, When, and How to Avoid False Negatives

Accurate diagnosis is foundational — both for confirming infection before treatment and for verifying eradication afterwards. The available tests fall into two categories: non-invasive (preferred for most clinical scenarios) and invasive (endoscopy-based, reserved for patients requiring upper endoscopy for other indications).

The Urea Breath Test (UBT)

The urea breath test exploits H. pylori's defining metabolic activity — urease production. The patient ingests a small amount of labelled urea (carbon-13 or carbon-14). If H. pylori is present, its urease cleaves the urea, releasing labelled CO₂ that is absorbed and exhaled. Exhaled breath is collected and analysed.

The UBT has sensitivity and specificity both exceeding 95%, making it the gold standard non-invasive test for both diagnosis and test-of-cure confirmation. It reflects current, active infection across the entire stomach rather than a single biopsy site. Key caveats:

• Stop proton pump inhibitors (PPIs) at least 2 weeks before testing — PPIs suppress H. pylori activity and cause false negatives
• Stop bismuth and antibiotics at least 4 weeks before testing
• H₂-receptor antagonists should be stopped 24–48 hours before testing
• Carbon-13 UBT is preferred during pregnancy (avoids radiolabelled carbon-14)

Stool Antigen Test (SAT)

The stool antigen test detects H. pylori proteins in a stool sample using monoclonal antibody-based immunoassays. Its accuracy is comparable to the UBT — sensitivity 94%, specificity 97% — and it is cheaper, does not require a clinic visit, and can be performed at home using commercial test kits. The same drug-washout rules apply as for the UBT. Monoclonal antibody-based SATs are significantly more accurate than older polyclonal versions and should be specified when ordering.

Serology (Blood Antibody Testing)

Serological tests detect IgG antibodies against H. pylori. They are inexpensive and widely available but have a critical limitation: antibodies persist for months to years after successful eradication. Serology cannot distinguish active from past infection and should never be used to confirm eradication. Its main utility is in epidemiological research and, in some guidelines, as an initial screening test in young patients with dyspepsia in high-prevalence populations where the positive predictive value is adequate.

Endoscopy-Based Tests

Upper endoscopy (gastroscopy) allows direct visualisation of the gastric mucosa with biopsy. Biopsy-based tests include the rapid urease test (RUT — fast, cheap, highly accurate), histology (gold standard for detecting atrophy, metaplasia, and dysplasia), and culture (essential for antibiotic susceptibility testing when resistance is suspected). Endoscopy is indicated in patients over 60 with new dyspepsia, patients with alarm symptoms (unintended weight loss, dysphagia, haematemesis, iron deficiency anaemia), and when empiric treatment has failed.

Treatment: Triple Therapy, Bismuth Quadruple Therapy, and the Resistance Crisis

The central challenge in H. pylori treatment is not the bacterium itself — it is antibiotic resistance. Clarithromycin resistance in particular has risen dramatically over the past two decades, transforming what was once a straightforward infection to treat into a nuanced clinical problem requiring region-specific approaches and, increasingly, susceptibility testing before prescribing.

Standard Triple Therapy: The Original Regimen

Standard triple therapy (STT) consists of a proton pump inhibitor (PPI) + clarithromycin + amoxicillin, taken twice daily for 7–14 days. It was the dominant first-line regimen globally for over two decades, achieving eradication rates above 80% when clarithromycin resistance was low. The rationale is logical: the PPI raises gastric pH, creating a more favourable environment for antibiotic activity; clarithromycin inhibits bacterial protein synthesis; amoxicillin disrupts cell wall synthesis.

However, as clarithromycin resistance rates have climbed above 15–20% in many Western countries and above 30% in parts of Southern Europe and East Asia, eradication rates with STT have fallen to unacceptable levels — below 70% in some regions. Current international guidelines (Maastricht VI, ACG 2022) recommend using STT only where local clarithromycin resistance is confirmed to be below 15%, or when individual susceptibility testing confirms the patient's strain is clarithromycin-sensitive.

Bismuth Quadruple Therapy: The New First-Line Standard

Bismuth quadruple therapy (BQT) combines bismuth subsalicylate or subcitrate + metronidazole + tetracycline + a PPI, typically taken for 10–14 days. It achieves eradication rates of 85–95% and, critically, is not significantly affected by clarithromycin resistance. Bismuth itself has direct antimicrobial activity against H. pylori and does not suffer from the resistance mechanisms that undermine macrolide therapy.

The complexity of the four-drug regimen (multiple pills, multiple daily doses) has historically been cited as a barrier to adherence, but pre-packaged combination products (Pylera in the US and Europe) have simplified administration. BQT is now recommended as preferred first-line therapy by the American College of Gastroenterology (ACG) 2022 guidelines in the United States, where clarithromycin resistance has exceeded the 15% threshold nationally.

Concomitant and Sequential Therapy

Concomitant therapy combines a PPI with clarithromycin, amoxicillin, and metronidazole simultaneously for 10–14 days. By including metronidazole alongside clarithromycin, it partially overcomes clarithromycin resistance and achieves eradication rates of 85–90%. It is preferred in regions with dual clarithromycin + metronidazole resistance below 10%.

Sequential therapy uses a PPI + amoxicillin for 5–7 days, then switches to a PPI + clarithromycin + metronidazole (or tinidazole) for another 5–7 days. The rationale is that amoxicillin first depletes the bacterial cell wall, improving clarithromycin uptake in the second phase. Eradication rates are 85–90% in low-resistance settings but fall sharply when dual resistance is present.

Levofloxacin-Based Rescue Therapy

For patients who fail first-line treatment, levofloxacin triple therapy (levofloxacin + amoxicillin + PPI for 10–14 days) is a common second-line option. It achieves 75–85% eradication in treatment-naive fluoroquinolone strains. However, fluoroquinolone resistance is rising globally — approaching 20–30% in some regions — making susceptibility testing before prescribing levofloxacin increasingly important.

Vonoprazan-Based Regimens: The Emerging Standard

Vonoprazan (VPZ) is a potassium-competitive acid blocker (P-CAB) that provides more potent and consistent acid suppression than conventional PPIs. Vonoprazan-based triple therapy (VPZ + clarithromycin + amoxicillin) has demonstrated eradication rates exceeding 90% — even in clarithromycin-resistant strains — in Japanese and US trials. Approved by the FDA in 2022 (as Voquezna Triple Pak and Dual Pak), vonoprazan-based regimens represent the most significant advance in H. pylori treatment in decades and are expected to become first-line in US guidelines as real-world adoption grows.

Antibiotic Resistance: The Defining Challenge of Modern H. Pylori Treatment

Antibiotic resistance is not a future concern for H. pylori treatment — it is the defining clinical reality today. The WHO has flagged clarithromycin-resistant H. pylori as a high-priority antibiotic-resistant pathogen. Understanding the resistance landscape is essential for any clinician or patient navigating treatment decisions.

Why Clarithromycin Resistance Has Surged

Clarithromycin resistance in H. pylori arises from point mutations in the 23S rRNA gene (most commonly A2142G, A2143G), which prevent the antibiotic from binding to the ribosome. Unlike many resistance mechanisms, these mutations are stable — resistant strains remain resistant permanently. Prior macrolide use for any indication (respiratory infections, dental procedures, sinusitis) is the dominant driver of pre-existing resistance at the individual level. At the population level, high antibiotic prescribing rates correlate directly with regional resistance prevalence.

Current clarithromycin resistance rates by region:

• United States: 25–30% (national average; higher in certain populations)
• Western Europe: 15–30% (lowest in Northern Europe, highest in Southern Europe)
• East Asia: 20–40% (rising rapidly in China and South Korea)
• Developing nations: Variable; often under-measured due to limited surveillance

The Case for Susceptibility Testing Before Prescribing

Culture-based susceptibility testing — growing H. pylori from a gastric biopsy and exposing it to antibiotics — allows clinicians to select a regimen the patient's specific strain will respond to. This approach, called culture-guided therapy, consistently achieves eradication rates above 90% regardless of regional resistance patterns. The barrier has historically been that it requires endoscopy for biopsy collection and takes weeks for results.

Emerging molecular tests (PCR-based resistance detection from biopsy or stool) are changing this equation. These can identify resistance mutations in clarithromycin, fluoroquinolones, and tetracycline within hours, without the need for culture. They remain expensive and not universally available, but represent the direction of travel in high-income healthcare systems.

Metronidazole and Tetracycline Resistance

Metronidazole resistance rates are high globally (30–40%) but clinically relevant resistance is partially overcome by using high doses or extending treatment duration. Tetracycline resistance remains low (<5% in most regions), which is why bismuth quadruple therapy — which combines both antibiotics — maintains high efficacy even in clarithromycin-resistant environments.

Post-Eradication Recovery: Probiotics, Gut Microbiome, and Long-Term Monitoring

Eradicating H. pylori is not the end of the story — it is the beginning of gut recovery. Antibiotic therapy, particularly broad-spectrum regimens like bismuth quadruple therapy, cause collateral damage to the broader gut microbiome that can persist for months. Understanding what happens post-eradication and how to support recovery is essential for optimal outcomes.

Antibiotic Disruption of the Gut Microbiome

A 14-day course of triple or quadruple antibiotic therapy significantly reduces gut microbial diversity. Studies using 16S rRNA sequencing demonstrate that post-treatment microbiome composition diverges substantially from baseline for 4–8 weeks, with reductions in beneficial Bifidobacterium and Lactobacillus species and, in some subjects, expansions of opportunistic pathogens including Clostridium difficile. Most patients experience some combination of diarrhoea, bloating, and altered bowel habits during and after treatment — symptoms that are both mechanistically explained by dysbiosis and amenable to probiotic intervention.

Evidence for Probiotics in H. Pylori Treatment

The evidence for adjunctive probiotic use during H. pylori eradication therapy is substantial and consistent across multiple meta-analyses:

• Side effect reduction: Probiotics reduce the incidence of diarrhoea, nausea, and epigastric discomfort associated with antibiotic therapy by 30–50%. This translates directly to better treatment adherence and therefore higher eradication rates.
• Eradication rate improvement: Meta-analyses report a modest but statistically significant improvement in eradication rates (5–10 percentage points) when probiotics are co-administered. The mechanism likely involves direct antimicrobial activity against H. pylori and improved mucosal barrier function.
• Best-evidenced strains: Lactobacillus reuteri (particularly DSM 17938 and ATCC PTA 6475), Saccharomyces boulardii CNCM I-745, and multi-strain Lactobacillus combinations have the strongest clinical trial support.

Timing matters: probiotics should be started simultaneously with the antibiotic course and continued for at least 4 weeks after completing antibiotics to support microbiome recovery. When taking antibiotics, separate the probiotic dose from the antibiotic by at least 2 hours to avoid direct inactivation.

Diet and Lifestyle During Recovery

The post-eradication period is an opportunity to build a gut environment inhospitable to H. pylori re-infection while supporting mucosal healing. Evidence-supported strategies include:

• Fermented foods: Yoghurt, kefir, kimchi, and sauerkraut provide live bacterial cultures and have demonstrated modest anti-H. pylori activity in pilot studies. They also accelerate microbiome recovery post-antibiotics.
• Sulforaphane (broccoli sprouts): Multiple randomised trials demonstrate that sulforaphane-rich broccoli sprout extract reduces H. pylori colonisation density and gastric inflammation. While not sufficient as monotherapy, it may help prevent re-infection.
• Reduce NSAID and aspirin use: NSAIDs independently damage gastric mucosa. H. pylori eradication dramatically reduces — but does not completely eliminate — ulcer risk in NSAID users. Continuing high-dose NSAIDs post-eradication undermines mucosal healing.
• Limit alcohol and smoking: Both impair gastric mucosal healing and are associated with higher H. pylori treatment failure rates.

Long-Term Monitoring After Eradication

For patients with confirmed eradication and no pre-existing atrophic gastritis or intestinal metaplasia, ongoing endoscopic surveillance is not generally required. However, patients with documented atrophic gastritis, intestinal metaplasia, or dysplasia require periodic surveillance endoscopy (typically every 1–3 years depending on risk stratification) because these pre-malignant lesions may persist and progress even after H. pylori is cleared.

Re-infection rates post-eradication are low in high-income countries (<1–2% per year) but higher in low-income settings (5–15% per year) due to ongoing environmental exposure. Testing-of-cure results that become positive months after a previous negative test suggest re-infection rather than treatment failure.

Frequently Asked Questions

Can I get H. pylori again after successful eradication?

Yes, but it is uncommon in developed countries — re-infection rates are below 1–2% per year in North America and Northern Europe. In regions with poor sanitation and high endemic prevalence, re-infection rates can reach 5–15% annually. Good hand hygiene, safe food and water practices, and avoiding sharing utensils reduce re-infection risk.

Should everyone with H. pylori be treated, even if asymptomatic?

Current major guidelines (ACG, European Maastricht VI) recommend a "test and treat" strategy — meaning that confirmed H. pylori infection warrants treatment regardless of whether symptoms are present. The rationale is the cumulative risk of ulcer disease, MALT lymphoma, and gastric cancer over a lifetime of untreated infection. The risk-benefit calculation overwhelmingly favours treatment.

What if I'm allergic to penicillin?

Amoxicillin is a penicillin antibiotic. Penicillin-allergic patients should receive bismuth quadruple therapy (which does not contain amoxicillin) or, after confirming the allergy is genuine, levofloxacin-based therapy. True penicillin allergy is rarer than reported — skin testing can clarify allergy status if needed.

How long until peptic ulcer symptoms resolve after eradication?

Epigastric pain and dyspepsia typically improve within 2–4 weeks of completing treatment, as the inflammatory process settles. Ulcer healing (confirmed endoscopically) takes 4–8 weeks for duodenal ulcers and 8–12 weeks for gastric ulcers. Some clinicians continue PPIs for 4–8 weeks post-antibiotics in confirmed ulcer patients to ensure complete mucosal healing.

Is H. pylori testing recommended for family members of an infected person?

Guidelines vary. Many gastroenterologists recommend testing first-degree family members — particularly household contacts and the partners of infected individuals — especially where there is a family history of gastric cancer. The test-and-treat approach is safe and low-cost, and early identification prevents years of ongoing infection.